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Introduction
NO, which may be synthesized by any of the three isoforms
of NOS, is a vasodilator of the pulmonary circulation in
many mammals. NO has been proposed as a modulator of
vascular tone and structure in the pulmonary circulation,
and previous studies using NOS inhibitors [1,2] suggested
that inhibition of NO increases acute hypoxic pulmonary
vasoconstriction. Chronic NOS inhibition did not lead to
development of pulmonary hypertension [3], however, pos-
sibly because of a decrease in cardiac output. These dis-
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Background: The importance of nitric oxide (NO) in hypoxic pulmonary hypertension has been
demonstrated using nitric oxide synthase (NOS) knockout mice. In that model NO from endothelial
NOS (eNOS) plays a central role in modulating pulmonary vascular tone and attenuating hypoxic
pulmonary hypertension. However, the normal regulation of NOS expression in mice following hypoxia
is uncertain. Because genetically engineered mice are often utilized in studies of NO, we conducted
the present study to determine how hypoxia alters NOS expression in wild-type mice.
Method: Mice were exposed to sea level, ambient conditions (5280 feet) or severe altitude (17,000
feet) for 6 weeks from birth, and hemodynamics and lung NOS expression were assessed.
Results: Hypoxic mice developed severe pulmonary hypertension (right ventricular systolic pressure
[RVsP] 60 mmHg) as compared with normoxic mice (27 mmHg). Using quantitative reverse-
transcription PCR, it was found that expressions of eNOS and inducible NOS (iNOS) increased 1.5-
fold and 3.5-fold, respectively, in the lung. In addition, the level of lung eNOS protein was increased,
neuronal NOS (nNOS) protein was unchanged, and iNOS was below the limit of detection.
Immunohistochemistry demonstrated no change in lung iNOS or nNOS staining in either central or
peripheral areas, but suggested increased eNOS in the periphery following hypoxia.
Conclusion: In mice, hypoxia is associated with increases in lung eNOS, possibly in iNOS, but not in
nNOS; this suggests that the pattern of lung NOS expression following hypoxia must be considered in
studies using genetically engineered mice.
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crepancies have been addressed in recent studies using
mice that are deficient in NOS isoforms.
Three isoforms of NOS are found in the lung. The principle
isoform that is found in the pulmonary vasculature is
eNOS [4]. iNOS is expressed in airway epithelium, and
airway and vascular smooth muscle [5,6], whereas nNOS
is expressed in the bronchial epithelium and lung nervous
tissue [4,5,7,8]. Thus, all three NOS isoforms could con-
tribute to modulation of pulmonary vascular tone. Studies
using knockout mice for each of these isoforms [9–12]
suggest that eNOS-derived NO is important in modulating
basal pulmonary vascular tone, as well as in attenuating
the development of pulmonary hypertension.
Severe sustained hypoxia causes pulmonary hypertension in
many animals. Upregulation of all three NOS isoforms fol-
lowing severe hypoxia has been reported in rats [4,13–16].
Less is certain about the expression of NOS in the murine
lung following hypoxia, with previous reports [17,18] sug-
gesting an increase in lung eNOS and iNOS levels. We
therefore hypothesized that NOS isoforms are upregulated
following hypoxia and that this may account for the
increased susceptibility to hypoxic pulmonary hypertension
in mice that lack eNOS [9,12]. In the present study we
exposed wild-type mice to severe hypobaric hypoxia from
birth and measured NOS mRNA and protein levels. We
then compared the findings with localization of NOS protein
in the lung as assessed using immunohistochemistry.
Materials and methods
Mice
We studied F1-generation SV129 (Taconic, Germantown,
NY, USA) and C57BL/6 (Jackson Laboratories, Bar
Harbor, ME, USA) mice at age 6 weeks.
Exposure environments
Within 24–36 h of birth, pups and dam were placed in
ambient conditions, hypobaric hypoxia (simulating an alti-
tude of 17,000 feet), or hyberbaric normoxia (simulating
sea level). Exposure was continuous, with minimal inter-
ruption for animal care. At 21 days the dam was removed
and animals were sorted by sex. At 6 weeks animals of
both sexes were removed for study.
Right ventricular pressure measurements
RVsP was measured as previously described [9]. Briefly,
mice were anesthetized with ketamine/xyalazine
(100/15 mg/kg), placed supine while spontaneously
breathing room air, and a 26-gauge needle was intro-
duced percutaneously into the thorax via a subxyphloid
approach; RVsP was recorded. Blood was drawn and
animals were killed. The thorax was opened and the lungs
were flushed with cold PBS. The right lung was frozen for
protein and RNA measurement, and the left lung was fixed
for histologic evaluation.
Western blotting
Frozen lung tissue was homogenized in ice cold 750 µl
radioimmunoprecipitation assay (RIPA) buffer (1 × PBS,
1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1%
SDS) plus protease inhibitors (30 µl/ml RIPA aprotinin,
10 µl/ml RIPA 100 mmol/l sodium orthovanadate).
Samples were triturated two to three times through 21-
guage then 25-gauge needles, and 10 µl/ml RIPA
10 mg/ml phenyl methylsulfonyl fluoride was added.
Samples were centrifuged twice at 4°C and 14,000 rpm.
Protein concentration was determined using the Bradford
method (Bio-Rad Laboratories, Hercules, CA, USA).
Protein 10 µg (eNOS) or 80 µg (nNOS and iNOS) were
separated by SDS-PAGE under reducing conditions (1%
β-mercaptoethanol) using 8–16% gradient gels (Invitro-
gen, Carlsbad, CA, USA). Coomassie blue staining was
used to verify equal loading of gel. Gels were transferred
in 20% methanol to polyvinylidene difluoride membrane
(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Blots were blocked (0.5% Tween 20, 1% milk) and incu-
bated with primary antibody for 45 min at 37°C (1:1500
anti-eNOS mono [BD Transduction Laboratories, San
Diego, CA, USA]; 1:1500 anti-nNOS poly [Zymed Labora-
tories, South San Francisco, CA, USA]; 1:200 anti-iNOS
poly [Affinity Bioreagents, Golden, CO, USA]; and 1:1500
anti-β-actin mono [Sigma A5441; Sigma-Aldrich, St Louis,
MO, USA]). Blots were washed and incubated with sec-
ondary antibody (1:1500 horseradish peroxidase) conju-
gated antimouse (eNOS) or antirabbit (nNOS, iNOS, and
β-actin) for 45 min at 37°C. Blots were developed with
Enhanced Chemiluminescence (Amersham Pharmacia
Biotech). INOS-positive control was lipopolysaccharide-
treated mouse spleen protein and nNOS-positive control
was mouse brain protein.
Quantitative reverse-transcription polymerase chain
reaction
Total RNA was extracted from 100 mg of frozen lung
using Tri-reagent (Molecular Research Center, Inc.,
Cincinnati, OH, USA) and the final product was resus-
pended in 20 µl diethylpyro carbonate (depC) H2O. RNA
was quantified and samples with A260/A280 >1.8 were
used. Samples were diluted in depC H2O and 50 ng were
used in quantitative one-tube reverse-transcription PCR
(Applied Biosystems, Foster City, CA, USA). RNA quantity
was determined using 18S rRNA primers/probes (Applied
Biosystems) and eNOS, iNOS and nNOS expression
determined using the primer/probe sequences shown in
Table 1. Message abundance was determined by dividing
the quantity of message of interest by the quantity of 18S
ribosomal RNA.
Immunohistochemistry
Left lungs were inflated with 1% agarose, fixed in methyl
carnoys (60% methanol, 30% chloroform and 10% glacial
acetic acid), embedded in paraffin, and sectioned. SectionsRespiratory Research    Vol 2 No 5 Fagan et al
were stained with anti-NOS antibodies (eNOS, BD Trans-
duction Laboratories N30020, 1:400 dilution; iNOS, Zymed
Laboratories 61-7000, 1:1000 dilution; nNOS, Transduc-
tion N32030, 1:500 dilution), developed with 3,3′-
diaminobenzidine, and counterstained with hematoxylin.
Hematocrit and nitric oxide metabolite measurements
Heparinized blood 100 µl was placed in capillary tubes
and hematocrit determined by standard techniques [9].
The remainder of the blood was spun at 4000 rpm for
10 min, and plasma removed and frozen. Later, samples
were thawed and centrifuged at 15,000 rpm for 20 min.
Plasma NO metabolites (NO, NO2
–, NO3
–, peroxynitrate,
and nitrosothiols) were measured using a NO chemilumi-
nescence analyzer (Ionics Instrument Business Group,
Boulder, CO, USA). Plasma samples 1 µl were added to
2 ml vanadium III chloride (Sigma-Aldrich) dissolved in 1N
HCl at 90°C to reduce all NO metabolites to NO. NO was
driven into the chemiluminescence detector by bubbling
with argon.
Statistical analysis
Data are expressed as mean ± standard error of the mean.
Data were analyzed using analysis of variance, and
P < 0.05 is considered statistically significant.
Results
Measurements of pulmonary hypertension
RVsP was measured as an index of pulmonary arterial
pressure. As shown in Fig. 1, RVsP was elevated in
animals that were exposed to hypobaric hypoxia as com-
pared with those that were exposed to sea level and
ambient conditions. Hypoxic animals were also more poly-
cythemic than were normoxic animals (70% ± 4% in
hypoxic animals versus 45% ± 3% and 42% ± 3% for
animal subjected to sea level and ambient conditions,
respectively; P < 0.001).
Western blotting
As shown in Fig. 2, lung eNOS protein levels were
increased following hypoxia, with a trend toward increased
eNOS in ambient versus sea level conditions. However,
iNOS protein was below the limit of detection following
any level of hypoxic exposure (positive control was
lipopolysaccharide-treated mouse spleen) and using
several different antibodies (Affinity Bioreagents and BD
Transduction Laboratories; Affinity Bioreagents blot
shown), and nNOS was unchanged among the three
experimental groups (positive control was mouse brain).
Quantitative reverse-transcription polymerase chain
reaction
eNOS expression in the lung, as studied using quantitative
reverse-transcription PCR, was increased 1.5-fold follow-
ing hypoxia as compared with normoxic conditions,
whereas iNOS expression was increased 3.5-fold (Fig. 3).
Immunohistochemistry
Localization of NOS in mouse lung was determined using
antibodies specific for eNOS, iNOS, and nNOS (Fig. 4).
eNOS levels were increased following hypoxia, and the
staining was more intense in large vessels and extended
out to the periphery of the lung, and was also found in
smaller vessels. In contrast, iNOS and nNOS were limited
primarily to the airway epithelium, and their levels did not
increase following exposure to hypoxia. This was con-
firmed using quantitative image analysis (data not shown).
Table 1
Primer/probe sequences used for determination of nitric oxide
synthase isoform expression
NOS isoform Primer/probe
eNOS Forward: TCTGCGGCGATGTCACTATG
Reverse: CATGCCGCCCTCTGTTG
Probe: CCAGCGTCCTGCAAACCGTGC
iNOS Forward: TGACGCCAAACATGACTTCAG
Reverse: GCCATCGGGCATCTGGTA
Probe: AATTCACAGCTCAATCCGGTACGCTGG
nNOS Forward: GACTGATGGCAAGCATGACTTC
Reverse: GCCCAAGGTAGAGCCATCTG
Probe: TGGAACTCGCAGCTCATCCGCTATG
eNOS = endothelial nitric oxide synthase; iNOS = inducible nitric
oxide synthase; nNOS = neuronal nitric oxide synthase; NOS = nitric
oxide synthase.
Figure 1
Right ventricular systolic pressure (RVsP) in mice exposed to sea level
conditions (SL, n = 5), ambient conditions (DEN, n = 9), or hypobaric
hypoxia (HA, n = 6) for 6 weeks after birth. *P < 0.005 versus SL or DEN.Nitric oxide metabolites
To determine whether the increase in NOS in the pul-
monary circulation following hypoxia resulted in increased
NO, we measured plasma NO metabolites (Fig. 5). There
was a modest increase in levels of NO metabolites in
animals exposed to hypoxia as compared with sea level or
ambient conditions.
Discussion
The major finding of this work was the upregulation of lung
expression of eNOS and possibly iNOS in mice with
severe hypoxia-induced pulmonary hypertension. The
increased eNOS was correlated with increased immuno-
localization to the periphery of the lung. This, however,
was not observed for iNOS or nNOS. Additionally, we
found increased severity of pulmonary hypertension in
animals exposed to hypoxia during postnatal development.
The pulmonary hypertension in mice exposed to hypoxia
from birth was more severe than we had observed in previ-
ous studies of 4 weeks of hypoxia in mature animals [9].
The degree of polycythemia was also greater in these
animals than in previous reports, and might have con-
tributed to the increase in pulmonary pressure due to
increased viscosity [19]. This suggests that either the
duration of hypoxic exposure or exposure from neonatal
Available online http://respiratory-research.com/content/2/5/306
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Figure 2
Lung nitric oxide synthase (NOS) protein. (a) Western blots of homogenized whole lung from mice exposed to sea level conditions (S, n = 5),
ambient conditions (D, n = 4), or hypobaric hypoxia (H, n = 5) for endothelial NOS (eNOS; 140 kDa), inducible NOS (iNOS; 130 kDa), neuronal
NOS (nNOS; 164 and 160 kDa), and β-actin (42 kDa). Positive control is present for iNOS (lipopolysaccharide-treated mouse spleen protein) and
nNOS (mouse brain protein). nNOS protein on Western analysis has previously been reported to appear as a doublet [45]. MW, molecular weight
marker. (b) Densitometry evaluation for eNOS protein comparing sea level (SL, n = 5) with ambient conditions (DEN, n = 3) and hypobaric hypoxia
(HA, n = 5). *P < 0.05 SL versus HA.
Figure 3
Quantitative reverse-transcription PCR for endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), and neuronal NOS (nNOS) in
homogenized whole lungs from mice exposed to sea level conditions (SL, n = 5), ambient conditions (DEN, n = 4), or hypobaric hypoxia (HA, 
n = 5) for 6 weeks after birth. *P < 0.05 versus SL, #P < 0.05 versus DEN.life provided additional physiologic stress that was not
seen in more mature animals [9]. No animals died,
however, suggesting that the stress was not sufficiently
severe to decrease survival during the study period. This
observation of increased susceptibility to hypoxic pul-
monary hypertension in younger, developing animals is in
agreement with previous reports [20,21].
The increase in eNOS protein and mRNA levels, and the
peripheral immunolocalization is in accord with previous
reports [13,14,18]. LeCras et al. [13] found that the
amount of eNOS protein was increased in hypoxic, hyper-
tensive rat lungs, and that this was not entirely due to the
presence of hypertension and increased shear stress, but
was also due to hypoxia. This is further supported by Tyler
et al. [15], who found that eNOS protein levels were
increased in rats with hypoxic pulmonary hypertension but
not in those with chemical-induced (monocrotaline) or
genetic (fawn-hooded rat) pulmonary hypertension [15].
As in the present study, increased eNOS levels correlated
with de novo expression in the small resistance vessels in
the lung [14,18]. The mechanism by which hypoxia
increases eNOS expression is poorly understood because
a hypoxia responsive element has not yet been identified
in the eNOS promoter. Recently, altering the redox state
of pulmonary artery endothelial cells in culture suggested
that activation of redox-sensitive transcription factor acti-
vator protein-1 during hypoxia may be responsible for the
increase in eNOS expression [22]. Despite the increase in
eNOS, however, the mice developed severe pulmonary
hypertension; this suggests either that NO production was
not increased (see below) or that NO was consumed.
Under more physiologically relevant levels of hypoxia, the
central role of eNOS in protecting against hypertension is
supported by our observation that loss of eNOS leads to
increased acute hypoxic vasoconstriction and develop-
ment of pulmonary hypertension [9–12].
In contrast to the observations with eNOS, iNOS
message was increased but iNOS protein remained below
the limit of detection in the lungs of hypoxic, hypertensive
Respiratory Research    Vol 2 No 5 Fagan et al
Figure 4
Lung nitric oxide synthase (NOS) immunolocalization. Lung endothelial
NOS (eNOS) immunostaining in (a) normoxic versus (b) hypoxic mice,
demonstrating an increase in peripheral distribution of eNOS (arrow,
red staining). Lung inducible NOS (iNOS) immunostaining in (c)
normoxic versus (d) hypobaric mice, demonstrating no difference in
the airway epithelial localization of iNOS (arrow, brown staining). Lung
neuronal NOS (nNOS) immunostaining in (e) normoxic versus (f)
hypoxic mice, demonstrating no change in airway epithelial distribution
of nNOS (arrow, brown staining). Magnification 40×.
Figure 5
Plasma nitric oxide metabolites (NOX) from mice exposed to sea level
conditions (SL, n = 5), ambient conditions (DEN, n = 9), or hypobaric
hypoxia (HA, n = 6) for 6 weeks after birth. *P < 0.05 versus DEN.mice. Previously, LeCras et al. [14] reported an increase in
both iNOS mRNA and protein levels in rat lungs following
hypoxia. In the present study, however, the increase in
iNOS mRNA levels was not associated with detectable
iNOS protein, using several different antibodies, in mice.
This is in contrast to the study of Quinlan et al. [17], in
which increased lung iNOS protein levels in adult mice fol-
lowing hypoxia was reported. This discrepancy may be
due to differences between the present study and that
report. Specifically, animals in our experiments are a differ-
ent strain and were housed in sealed hypobaric chambers
as opposed to being flushed with 10% O2 gas. The hypo-
baric chambers used in the present study have a higher
rate of air exchange than other hypoxic gas chambers,
thus limiting the build-up of waste products, including
ammonia, that may contribute to lung inflammation and
induction of iNOS, as the combination of hypoxia and
inflammation has previously been reported to increase
iNOS expression [23]. Thus, the increased iNOS reported
previously may be due to the combination of hypoxia and
inflammation [23]. Others have also reported that lung
iNOS protein was detectable only after lipopolysaccharide
administration [24].
The iNOS promoter contains a hypoxia responsive
element, and the increase in iNOS transcription in
hypoxia may be due to the transcription factor hypoxia-
inducible factor-1α [25–27]. Additionally, recent studies
also suggest that alterations in redox state during
hypoxia may also increase iNOS expression, similar to
eNOS, by activation of redox sensitive nuclear factor-κB
or activator protein-1 [28,29]. It is not known whether
hypoxia interferes with translation or degradation of
iNOS protein. In support of our current finding, however,
immunohistochemical localization of iNOS to the airway
did not change following hypoxia. We have recently
reported that mice deficient in iNOS do not have
increased pulmonary vasoreactivity, suggesting that
lung-derived iNOS is not an important modulator of
acute pulmonary vascular reactivity [10]. Mice deficient
in iNOS do have a slight increase in right ventricular
pressure, however, suggesting that iNOS, especially in
the upper airway, may contribute to modulation of
chronic pulmonary vascular tone [10]. Thus, the impor-
tance of iNOS in hypoxic pulmonary hypertension
remains uncertain.
In rat lungs, nNOS expression was increased following
hypoxia [4], but we did not find an increase in lung
nNOS in mice following hypoxia. Increased nNOS has
been suggested as a compensatory vasodilator in the
cerebral and coronary circulation of eNOS-deficient
mice, but its role in the pulmonary circulation is unknown
[8,30]. However, we previously demonstrated [10] that
nNOS does not appear to play a role in modulating tone
in the pulmonary circulation.
Although we did not look at the expression of NOS in
other rat vascular beds following hypoxia, other reports
suggest that the increase in NOS following hypoxia may
be species and tissue specific. Previous studies of NOS
expression in systemic and pulmonary endothelial cells
from different species in cultures [31–37] have yielded
conflicting results. Recently, Toporsian et al. [38] reported
in vivo downregulation of eNOS mRNA and protein levels
in the aorta of rats following prolonged hypoxia, which cor-
related with impaired endothelium-dependent vasorelax-
ation, whereas there was an increase in eNOS protein
levels in the lungs. Conversely, eNOS levels were
increased in hypoxic uterine, but not femoral or renal arter-
ies of pregnant sheep [39].
Whether increased NOS expression leads to increased
production of NO in vivo is controversial [40]. In piglets in
vivo, acute hypoxia caused decreased exhaled NO and
decreased aortic and pulmonary arterial plasma nitrite
levels [41]. Following chronic hypoxia in rats, Sato et al.
[42] found that plasma NO metabolite levels were
markedly increased compared with normoxic controls
when animals were exposed to 21% O2, but were not
increased when rats were breathing 10% O2. This sug-
gests that hypoxia inhibited NO production despite the
increase in NOS expression. There are several proposed
mechanisms for the discordance between NO production
and increased NOS expression in vitro and in vivo, includ-
ing impaired arginine uptake [43], decreased heat shock
protein-90 levels [44], and decreased O2 tension [42,40].
In agreement with previous studies, the plasma NO
metabolite content in the present study was minimally ele-
vated in the hypoxic group. Although we attempted to
keep the mice continuously hypoxic, a relatively brief
period of reoxygenation might account for the slight
increase in plasma NO metabolites seen in the hypoxic
animals, which is consistent with the observations of Sato
et al. [42]. Because the systemic and pulmonary vascula-
tures can both contribute to plasma NO metabolite levels,
if NOS was downregulated in the systemic circulation as
suggested by Toporsian et al. [38], then the lack of
increased NO metabolites could also be due to
decreased NOS activity in the systemic circulation.
However, those investigators did not observe any differ-
ence in plasma NO metabolites in normoxic versus
hypoxic rats in which aortic NOS was downregulated, but
did observe a decrease in acetylcholine-stimulated NO
release from aortic rings. The pattern of NOS expression
in vascular beds other than the lung following hypoxia in
mice is presently unknown.
Conclusion
In summary, we identified a unique pattern of NOS upreg-
ulation in the murine lung with severe hypoxia-induced pul-
monary hypertension, which may be important when
considering studies using NOS-deficient mice. The
Available online http://respiratory-research.com/content/2/5/306
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epresent study also suggests that exposure of neonatal
mice to hypoxia may lead to more severe pulmonary hyper-
tension than that observed in mature mice exposed to
hypoxia, and this warrants further study.
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